A novel p38α MAPK inhibitor suppresses brain proinflammatory cytokine up-regulation and attenuates synaptic dysfunction and behavioral deficits in an Alzheimer's disease mouse model

Journal of Neuroinflammation

Volumn 4, Issue , 2007, Pages

  Munoz, Lenka ^a,b   Ranaivo, Hantamalala ^a   Roy, Saktimayee M ^a   Hu, Wenhui ^a,c   Craft, Jeffrey M ^a,d   McNamara, Laurie K ^a   Chico, Laura Wing ^a   Van Eldik, Linda J ^a   Watterson, D Martin ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF SYDNEY   (Australia)

^c GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH   (China)

^d BARNES JEWISH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 PHENYL 4 (PYRIDIN 3 YL) 6 [4 (PYRIMIDIN 2 YL)PIPERAZIN 1 YL]PYRIDAZINE; 3 PHENYL 4 (PYRIDIN 4 YL) 6 [4 (PYRIMIDIN 2 YL)PIPERAZIN 1 YL]PYRIDAZINE; AMYLOID BETA PROTEIN; CYTOKINE; MITOGEN ACTIVATED PROTEIN KINASE 14; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; UNCLASSIFIED DRUG; AUTACOID; MW01 2 069A SRM; MW01-2-069A-SRM; NEW DRUG; PROTEIN KINASE INHIBITOR; PYRIDAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR DISORDER; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG MECHANISM; DRUG PENETRATION; DRUG SAFETY; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG UPTAKE; HIPPOCAMPUS; IN VIVO STUDY; LOW DRUG DOSE; MOUSE; NEUROLOGIC DISEASE; NONHUMAN; OUTCOME ASSESSMENT; PROTEIN SYNTHESIS INHIBITION; SYNAPTIC TRANSMISSION; UPREGULATION; ANIMAL; ANIMAL BEHAVIOR; BIOSYNTHESIS; BRAIN; C57BL MOUSE; CHEMISTRY; COMPARATIVE STUDY; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; HUMAN; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; PSYCHOLOGICAL ASPECT; SIGNAL TRANSDUCTION; SYNAPSE;

ALZHEIMER DISEASE; ANIMALS; BEHAVIOR, ANIMAL; BRAIN; CYTOKINES; DISEASE MODELS, ANIMAL; DRUGS, INVESTIGATIONAL; HUMANS; INFLAMMATION MEDIATORS; MAP KINASE SIGNALING SYSTEM; MICE; MICE, INBRED C57BL; MITOGEN-ACTIVATED PROTEIN KINASE 14; PROTEIN KINASE INHIBITORS; PYRIDAZINES; PYRIMIDINES; SYNAPSES; UP-REGULATION;

EID: 35348886061     PISSN: None     EISSN: 17422094     Source Type: Journal    
DOI: 10.1186/1742-2094-4-21     Document Type: Article

References (79)

1. Craft JM Watterson DM Van Eldik LJ Neuroinflammation: A potential therapeutic target Expert Opin Ther Targets 2005, 9:887-900. 10.1517/ 14728222.9.5.887 16185146
2. Griffin WS Sheng JG Royston MC Gentleman SM McKenzie JE Graham DI Roberts GW Mrak RE Glial-neuronal interactions in Alzheimer's disease: the potential role of a "cytokine cycle" in disease progression Brain Pathol 1998, 8:65-72. 9458167
3. Minagar A Shapshak P Fujimura R Ownby R Heyes M Eisdorfer C The role of macrophage/microglia and astrocytes in the pathogenesis of three neurologic disorders: HIV-associated dementia, Alzheimer disease, and multiple sclerosis J Neurol Sci 2002, 202:13-23. 10.1016/ S0022-510X(02)00207-1 12220687
4. Moisse K Strong MJ Innate immunity in amyotrophic lateral sclerosis Biochim Biophys Acta 2006, 1762:1083-1093. 16624536
5. Mrak RE Griffin WST Glia and their cytokines in progression of neurodegeneration Neurobiol Aging 2005, 26:349-354. 10.1016/ j.neurobiolaging.2004.05.010 15639313
6. Nagatsu T Sawada M Inflammatory process in Parkinson's disease: Role for cytokines Pharm Des 2005, 11:999-1016.
7. Orr CF Rowe DB Halliday GM An inflammatory review of Parkinson's disease Prog Neurobiol 2002, 68:325-340. 10.1016/S0301-0082(02)00127-2 12531233
8. Ringheim GE Conant K Neurodegenerative disease and the neuroimmune axis (Alzheimer's and Parkinson's disease, and viral infections) J Neuroimmunol 2004, 147:43-49. 10.1016/j.jneuroim.2003.10.013 14741426
9. Rothwell NJ Luheshi GN Interleukin 1 in the brain: Biology, pathology and therapeutic target Trends Neurosci 2000, 23:618-625. 10.1016/ S0166-2236(00)01661-1 11137152
10. Sargsyan SA Monk PN Shaw PJ Microglia as potential contributors to motor neuron injury in amyotrophic lateral sclerosis Glia 2005, 51:241-253. 10.1002/glia.20210 15846792
11. Craft JM Watterson DM Van Eldik LJ Human amyloid β-induced neuroinflammation is an early event in neurodegeneration Glia 2006, 53:484-490. 10.1002/glia.20306 16369931
12. Griffin WST Stanley LC Ling C White L MacLeod V Perrot LJ White CL Araoz C Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease Proc Natl Acad Sci USA 1989, 86:7611-7615. 298116 2529544 10.1073/pnas.86.19.7611
13. Craft JM Watterson DM Marks A Van Eldik LJ Enhanced susceptibility of S100B transgenic mice to neuroinflammation and neuronal dysfunction induced by intracerebroventricular infusion of human β-amyloid Glia 2005, 51:209-216. 10.1002/glia.20194 15810011
14. Craft JM Watterson DM Hirsch E Van Eldik LJ Interleukin 1 receptor antagonist knockout mice show enhanced microglial activation and neuronal damage induced by intracerebroventricular infusion of human beta-amyloid J Neuroinflammation 2005, 2:15-23. 1190207 15967035 10.1186/ 1742-2094-2-15
15. Li Y Liu L Kang J Sheng JG Barger SW Mrak RE Griffin WST Neuronal-glial interactions mediated by interleukin-1 enhance neuronal acetylcholinesterase activity and mRNA expression J Neurosci 2000, 20:149-155. 10627591
16. Griffin WST Liu L Li Y Mrak RE Barger SW Interleukin-1 mediates Alzheimer and Lewy body pathologies J Neuroinflammation 2006, 3:5-13. 1435743 16542445 10.1186/1742-2094-3-5
17. Sheng JG Ito K Skinner RD Mrak RE Rovnaghi CR Van Eldik LJ Griffin WST In vivo and in vitro evidence supporting a role for the inflammatory cytokine interleukin-1 as a driving force in Alzheimer pathogenesis Neurobiol Aging 1996, 17:761-766. 10.1016/0197-4580(96)00104-2 8892349
18. Sheng JG Zhu SG Jones RA Griffin WST Mrak RE Interleukin-1 promotes expression and phosphorylation of neurofilament and tau proteins in vivo Exp Neurol 2000, 163:388-391. 10.1006/exnr.2000.7393 10833312
19. Sheng JG Jones RA Zhou XQ McGinness JM Van Eldik LJ Mrak RE Griffin WS Interleukin-1 promotion of MAPK-p38 overexpression in experimental animals and in Alzheimer's disease: Potential significance for tau protein phosphorylation Neurochem Int 2001, 39:341-348. 10.1016/ S0197-0186(01)00041-9 11578769
20. Craft JM Watterson DM Frautschy SA Van Eldik LJ Aminopyridazines inhibit β-amyloid induced glial activation and neuronal damage in vivo Neurobiol Aging 2004, 25:1283-1292. 10.1016/j.neurobiolaging.2004.01.006 15465624
21. Craft JM Van Eldik LJ Zasadzki M Hu W Watterson DM Aminopyridazines attenuate hippocampus dependent behavioral deficits induced by human Aβ in a murine model of neuroinflammation J Mol Neurosci 2004, 24:115-122. 10.1385/JMN:24:1:115 15314259
22. Hu W Ralay Ranaivo H Roy SM Behanna HA Wing LK Munoz L Guo L Van Eldik LJ Watterson DM Development of a novel therapeutic suppressor of brain proinflammatory cytokine up-regulation that attenuates synaptic dysfunction and behavioral deficits Bioorg Med Chem Lett 2007, 17:414-418. 10.1016/j.bmcl.2006.10.028 17079143
23. Ralay Ranaivo H Craft JM Hu W Guo L Wing LK Van Eldik LJ Watterson DM Glia as a therapeutic target: Selective suppression of human amyloid-beta-induced upregulation of brain proinflammatory cytokine production attenuates neurodegeneration J Neurosci 2006, 26:662-670. 10.1523/JNEUROSCI.4652-05.2006 16407564
24. Braddock M Quinn A Targeting IL-1 in inflammatory disease: New opportunities for therapeutic intervention Nat Rev Drug Discov 2004, 3:330-339. 10.1038/nrd1342 15060528
25. Palladino MA Bahjat FR Theodorakis EA Moldawer LL Anti-TNF-alpha therapies: The next generation Nat Rev Drug Discov 2003, 2:736-746. 10.1038/nrd1175 12951580
26. Tobinick E Gross H Weinberger A Cohen H TNF-alpha modulation for treatment of Alzheimer's disease: A 6-month pilot study MedGenMed 2006, 8:25. 1785182 16926764
27. Rhen T Cidlowski JA Antiinflammatory action of glucocorticoids-new mechanisms for old drugs N Engl J Med 2005, 353:1711-1723. 10.1056/ NEJMra050541 16236742
28. Schacke H Docke WD Asadullah K Mechanisms involved in the side effects of glucocorticoids Pharmacol Ther 2002, 96:23-43. 10.1016/ S0163-7258(02)00297-8 12441176
29. Wing LK Behanna HA Van Eldik LJ Watterson DM Ralay Ranaivo H De novo and molecular target-independent discovery of orally bioavailable lead compounds for neurological disorders Curr Alzheimer Res 2006, 3:205-214. 10.2174/156720506777632844 16842097
30. Somera-Molena KC Robin B Somera CA Anderson C Koh S Behanna HA Van Eldik LJ Watterson DM Wainwright MS Glial activation links early-life seizures and long-term neurologic dysfunction: Evidence using a small molecule inhibitor of pro-inflammatory cytokine upregulation Epilepsia 2007 online May 23, 2007. doi:10.1111/j.1528-1167.2007.01135.x
31. Sams-Dodd F Drug discovery: Selecting the optimal approach Drug Discov Today 2006, 11: 465-472. 10.1016/j.drudis.2006.03.015 16635811
32. Sams-Dodd F Research and market strategy: How choice of drug discovery approach can affect market position Drug Discov Today 2007, 12:314-318. 10.1016/j.drudis.2007.02.014 17395091
33. Adams JL Badger AM Kumar S Lee JC p38 MAP kinase: Molecular target for the inhibition of pro-inflammatory cytokines Prog Med Chem 2001, 38:1-60. 11774793
34. Kaminska B MAPK signalling pathways as molecular targets for anti-inflammatory therapy - from molecular mechanisms to therapeutic benefits Biochim Biophys Acta 2005, 1754:253-262. 16198162
35. Kumar S Boehm J Lee JC p38 MAP kinases: Key signalling molecules as therapeutic targets for inflammatory diseases Nat Rev Drug Discov 2003, 2: 717-726. 10.1038/nrd1177 12951578
36. Kyriakis JM Avruch J Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation Physiol Rev 2001, 81:807-869. 11274345
37. Saklatvala J The p38 MAP kinase pathway as a therapeutic target in inflammatory disease Curr Opin Pharmacol 2004, 4:372-377. 10.1016/ j.coph.2004.03.009 15251131
38. Schieven GL The biology of p38 kinase: A central role in inflammation Curr Top Med Chem 2005, 5:921-928. 10.2174/1568026054985902 16178737
39. Dalrymple SA p38 mitogen activated protein kinase as a therapeutic target for Alzheimer's disease J Mol Neurosci 2002, 19:295-299. 10.1385/ JMN:19:3:295 12540055
40. Johnson GV Bailey CD The p38 MAP kinase signaling pathway in Alzheimer's disease Exp Neurol 2003, 183:263-268. 10.1016/S0014-4886(03)00268-1 14552867
41. Ferrer I Gomez-Isla T Puig B Freixes M Ribe E Dalfo E Avila J Current advances on different kinases involved in tau phosphorylation, and implications in Alzheimer's disease and tauopathies Curr Alzheimer Res 2005, 2:3-18. 10.2174/1567205052772713 15977985
42. Hensley K Floyd RA Zheng NY Nael R Robinson KA Nguyen X Pye QN Stewart CA Geddes J Markesbery WR p38 kinase is activated in the Alzheimer's disease brain J Neurochem 1999, 72:2053-2058. 10.1046/ j.1471-4159.1999.0722053.x 10217284
43. Pei JJ Braak E Braak H Grundke-Iqbal I Iqbal K Winblad B Cowburn RF Localization of active forms of C-jun kinase (JNK) and p38 kinase in Alzheimer's disease brains at different stages of neurofibrillary degeneration J Alzheimers Dis 2001, 3:41-48. 12214071
44. Sun A Liu M Nguyen XV Bing G P38 MAP kinase is activated at early stages in Alzheimer's disease brain Exp Neurol 2003, 183:394-405. 10.1016/ S0014-4886(03)00180-8 14552880
45. Zhu X Rottkamp CA Boux H Takeda A Perry G Smith MA Activation of p38 kinase links tau phosphorylation, oxidative stress, and cell cycle-related events in Alzheimer disease J Neuropathol Exp Neurol 2000, 59:880-888. 11079778
46. Zhu X Rottkamp CA Hartzler A Sun Z Takeda A Boux H Shimohama S Perry G Smith MA Activation of MKK6, an upstream activator of p38, in Alzheimer's disease J Neurochem 2001, 79:311-318. 10.1046/ j.1471-4159.2001.00597.x 11677259
47. Culbert AA Skaper SD Howlett DR Evans NA Facci L Soden PE Seymour ZM Guillot F Gaestel M Richardson JC MAPK-activated protein kinase 2 deficiency in microglia inhibits pro-inflammatory mediator release and resultant neurotoxicity. Relevance to neuroinflammation in a transgenic mouse model of Alzheimer disease J Biol Chem 2006, 281: 23658-23667. 10.1074/jbc.M513646200 16774924
48. Ferrer I Stress kinases involved in tau phosphorylation in Alzheimer's disease, tauopathies and APP transgenic mice Neurotox Res 2004, 6:469-475. 15658002
49. Giovannini MG Scali C Prosperi C Bellucci A Vannucchi MG Rosi S Pepeu G Casamenti F Beta-amyloid-induced inflammation and cholinergic hypofunction in the rat brain in vivo: Involvement of the p38MAPK pathway Neurobiol Dis 2002, 11:257-274. 10.1006/nbdi.2002.0538 12505419
50. Jin Y Yan EZ Fan Y Zong ZH Qi ZM Li Z Sodium ferulate prevents amyloid-beta-induced neurotoxicity through suppression of p38 MAPK and upregulation of ERK-1/2 and Akt/protein kinase B in rat hippocampus Acta Pharmacol 2005, 26:943-951. 10.1111/j.1745-7254.2005.00158.x
51. Savage MJ Lin YG Ciallella JR Flood DG Scott RW Activation of c-Jun N-terminal kinase and p38 in an Alzheimer's disease model is associated with amyloid deposition J Neurosci 2002, 22:3376-3385. 11978814
52. 1-42 -induced cell signaling and functional responses in human microglia J Neurosci 2006, 26:11652-11664. 10.1523/JNEUROSCI.2490-06.2006 17093087
53. Kim SH Smith CJ Van Eldik LJ Importance of MAPK pathways for microglial pro-inflammatory cytokine IL-1 beta production Neurobiol Aging 2004, 25:431-439. 10.1016/S0197-4580(03)00126-X 15013563
54. Koistinaho M Koistinaho J Role of p38 and p44/42 mitogen-activated protein kinases in microglia Glia 2002, 40:175-183. 10.1002/glia.10151 12379905
55. McDonald DR Bamberger ME Combs CK Landreth GE beta-Amyloid fibrils activate parallel mitogen-activated protein kinase pathways in microglia and THP1 monocytes J Neurosci 1998, 18:4451-4460. 9614222
56. Pyo H Jou I Jung S Hong S Joe E-h Mitogen-activated protein kinases activated by lipopolysaccharide and β-amyloid in cultured rat microglia Neuroreport 1998, 9:871-874. 10.1097/00001756-199803300-00020 9579682
57. Bhat NR Zhang P Lee JC Hogan EL Extracellular signal-regulated kinase and p38 subgroups of mitogen-activated protein kinases regulate inducible nitric oxide synthase and tumor necrosis factor-α gene expression in endotoxin-stimulated primary glial cultures J Neurosci 1998, 18:1633-1641. 9464988
58. Lee YB Schrader JW Kim SU p38 MAP kinase regulates TNF-α production in human astrocytes and microglia by multiple mechanisms Cytokine 2000, 12:874-880. 10.1006/cyto.2000.0688 10880231
59. Wermuth CG Similarity in drugs: Reflections on analogue design Drug Discov Today 2006, 11: 348-354. 10.1016/j.drudis.2006.02.006 16580977
60. Pardridge WM Blood-brain barrier delivery Drug Discov Today 2007, 12:54-61. 10.1016/j.drudis.2006.10.013 17198973
61. Dury K New methods in the chemistry of pyridazinones Angew Chem Int Ed 1965, 4:292-300. 10.1002/anie.196502921
62. Ravin̈a E Teran C Santana L Garcia N Estevez I Pyridazine derivatives, IX. Synthesis of 2H-pyridazin-3-ones with aroylpiperazinyl group Heterocycles 1990, 31:1967-1974.
63. Sotelo E Fraiz N Yanez M Laguna R Cano E Ravina E Pyridazines. Part 31: synthesis and antiplatelet activity of 4,5-disubstituted-6-phenyl-3(2H)-pyridazinones Chem Pharm Bull (Tokyo) 2002, 50:1574-1577. 10.1248/cpb.50.1574 12499593
64. Guo Y Shen H Solubility and Lipophilicity: Assessing physicochemical properties of lead compounds Methods in Pharmacology and Toxicology Optimization in Drug Discovery: In Vitro Methods Totowa, New Jersey: Humana Press Yan Z, Caldwell GW 2004, 1-17.
65. Nasal A Siluk D Kaliszan R Chromatographic retention parameters in medicinal chemistry and molecular pharmacology Curr Med Chem 2003, 10:381-426. 12570698
66. Streng WH Physical chemical characterization of drug substances Drug Discovery Today 1997, 2:415-426. 10.1016/S1359-6446(97)01077-5
67. Takacs-Novak K Avdeef A Interlaboratory study of log P determination by shake-flask and potentiometric methods J Pharm Biomed Anal 1996, 14:1405-1413. 10.1016/0731-7085(96)01773-6 8877846
68. Behanna HA Watterson DM Ranaivo HR Development of a novel bioavailable inhibitor of the calmodulin-regulated protein kinase MLCK: A lead compound that attenuates vascular leak Biochim Biophys Acta 2006, 1763:1266-1274. 10.1016/j.bbamcr.2006.08.007 16996151
69. Schumacher AM Schavocky JP Velentza AV Mirzoeva S Watterson DM A calmodulin-regulated protein kinase linked to neuron survival is a substrate for the calmodulin-regulated death-associated protein kinase Biochemistry 2004, 43:8116-8124. 10.1021/bi049589v 15209507
70. Velentza AV Wainwright MS Zasadzki M Mirzoeva S Schumacher AM Haiech J Focia PJ Egli M Watterson DM An aminopyridazine-based inhibitor of a pro-apoptotic protein kinase attenuates hypoxia-ischemia induced acute brain injury Bioorg Med Chem Lett 2003, 13:3465-3470. 10.1016/ S0960-894X(03)00733-9 14505650
71. Ackley DC Rockich KT Baker TR Metabolic stability assessed by liver microsomes and hepatocytes Methods in Pharmacology and Toxicology Optimization in Drug Discovery: In Vitro Methods Totowa, New Jersey: Humana Press Yan Z, Caldwell GW 2004, 151-162.
72. Hynes J Leftheris K Small molecule p38 inhibitors: Novel structural features and advances from 2002 - 2005 Curr Topics Med Chem 2005, 5:967-985. 10.2174/1568026054985920
73. Lee MR Dominguez C MAP kinase p38 inhibitors: Clinical results and an intimate look at their interactions with p38alpha protein Curr Med Chem 2005, 12:2979-2994. 10.2174/092986705774462914 16378500
74. Peifer C Wagner G Laufer S New approaches to the treatment of inflammatory disorders small molecule inhibitors of p38 MAP kinase Curr Top Med Chem 2006, 6:113-149. 10.2174/156802606775270323 16454763
75. Frautschy SA Hu W Kim P Miller SA Chu T Harris-White ME Cole GM Phenolic anti-inflammatory antioxidant reversal of Abeta-induced cognitive deficits and neuropathology Neurobiol Aging 2001, 22:993-1005. 10.1016/ S0197-4580(01)00300-1 11755008
76. Bhagwat SS Manning AM Hoekstra MF Lewis A Gene-regulating protein kinases as important anti-inflammatory targets Drug Discov Today 1999, 4:472-479. 10.1016/S1359-6446(99)01402-6 10481143
77. Hopkins AL Groom CR The druggable genome Nat Rev Drug Discov 2002, 1:727-730. 10.1038/nrd892 12209152
78. Russ AP Lampel S The druggable genome: An update Drug Discov Today 2005, 10:1607-1610. 10.1016/S1359-6446(05)03666-4 16376820
79. Li Y Liu L Barger SW Griffin WS Interleukin-1 mediates pathological effects of microglia on tau phosphorylation and on synaptophysin synthesis in cortical neurons through a p38-MAPK pathway J Neurosci 2003, 23:1605-1611. 12629164